BCMA
Other names: B-cell maturation antigen, TNFRSF17
BCMA is a marker on plasma cells and is the basis for several advanced therapies in multiple myeloma.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
BCMA is a protein that is found in many plasma cells, including myeloma cells. Therefore, this protein is used as a therapeutic target directed at these cells.
Clinical meaning
BCMA expression is a consideration in cellular therapy and bispecific antibodies for multiple myeloma that has undergone several lines of therapy.
Testing methods
- Immunohistochemistry (IHC)
A test that uses antibodies to mark specific proteins in tumour tissue.
- Flow cytometry
A test that rapidly measures cell-surface markers across many cells.
- Next-generation sequencing (NGS)
A test that reads many genes from one tumour sample to find actionable changes.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- Had BCMA expression assessed in recent bone marrow samples.
- History of previous therapy, including whether you have received anti-BCMA therapy.
- Facility and program requirements for cellular or bispecific antibody therapy.
Related drugs
- Teclistamab
BCMAxCD3 bispecific antibody
- Belantamab mafodotin
Anti-BCMA drug-antibody conjugate
- Idecabtagene vicleucel
Anti-BCMA CAR-T therapy
- Ciltacabtagene autoleucel
Anti-BCMA CAR-T therapy
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NO DATA
No studies in the latest registry data mention this marker in their description.
Check options based on your result
Share the BCMA result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Multiple Myeloma
Cancer type
Reason: Related through a biomarker
- BCMA positive
Molecular alteration
Reason: Related through a biomarker
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Related through a biomarker
- Immunotherapy
Treatment category
Reason: Related through a biomarker
- Belantamab mafodotin
Drug
Reason: Targets this marker
- Ciltacabtagene autoleucel
Drug
Reason: Targets this marker
To check
- Flow cytometry
Diagnostic test
Reason: Diperiksa melalui
- Immunohistochemistry (IHC)
Diagnostic test
Reason: Diperiksa melalui
- Next-generation sequencing (NGS)
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.